Previously, the investigators have demonstrated in vitro the excellent efficacy of marula oil-derived ceramide NPs in enhancing skin barrier function. The investigators's findings show that marula oil-derived ceramide NPs not only significantly reduces levels of inflammatory cytokines but also promotes the expression of key proteins in skin barrier integrity. These results suggest that marula oil-derived ceramide NPs may offer a more effective therapeutic option for skin barrier-disrupted diseases. Therefore, the investigators aim to further investigate the repair function of marula oil-derived ceramide NPs on the human epidermal barrier through a clinical trial.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluation of Transepidermal Water Loss (TEWL) Following Topical Facial Cream Application
Timeframe: Outcome assessments: baseline (Day 0), Day 7, and Day 28 (after 28 days of twice-daily cream application). Total study duration: 28 days.
Evaluation of Skin Hydration Following Application of a Topical Facial Cream
Timeframe: Outcome measures are assessed at baseline (Day 0), Day 7 (7 days after cream initiation), and Day 28 (28 days after cream initiation). Participants apply the cream twice daily throughout the 28-day study period.
Evaluation of Erythema Severity Using a* Color Value in Facial Skin
Timeframe: Measurements at Baseline (Day 0), Day 7, and Day 28 during the 28-day intervention period.
Quantitative Assessment of Facial Erythema Area.
Timeframe: Outcome assessed at Baseline (Day 0), Day 7 , and Day 28 during 28-day study.
Effect of Topical Facial Cream on Skin Thickness.
Timeframe: Assessments at Baseline (Day 0), Day 7 , and Day 28 during 28-day intervention period.
Effect of Topical Facial Cream on Skin Density
Timeframe: Outcome assessed at Baseline (Day 0), Day 7, and Day 28 during 28-day intervention period